Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Name: Kaimen Rigor review — Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Item: Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Rating: 100
Author: Alpha1

Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Zhou S, Li P, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Yao G, Fan Y, Lin J, Zhu X, Xu B

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 1 high issue for “Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Read full text (PMC)

DOI

10.1136/bmj-2025-087259

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/bad43a1e-af51-4b4c-9dba-565bea1f3cc6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/bad43a1e-af51-4b4c-9dba-565bea1f3cc6/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 1 high issue for “Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

5450a279ffdac244af0951e9ebf6ff3b494f931f1c5efa28c45bc18dd21aeb0a

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Paper source

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 103AuthenticityData authenticity concerns 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 RCT with rigorous design, clear reporting of ethics, resources, and statistics, and a concrete data availability statement. Minor reporting gaps include lack of explicit CONSORT adherence and a small inconsistency in the safety narrative versus Table 2.

Both reviewers classified the study as interventional; no divergence. The statistics verification covered only 3 tests (those with test statistics/CI); the remaining analyses were not machine-verified but no errors were flagged. The citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Data look implausibly cleanAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

Prior work is cited (CLEOPATRA, PHILA interim analysis) and the rationale for the study is clearly linked to the need for long-term survival data. The limitations of prior work (preliminary overall survival data) are explicitly addressed as the motivation for this updated analysis.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes the scientific rationale for dual HER2 blockade and the role of pyrotinib, citing the CLEOPATRA trial and prior PHILA interim results.

Evidence

“Among the dual anti-HER2 regimens, the combination of pertuzumab and trastuzumab along with docetaxel is the established standard of care for the initial treatment of patients with HER2 positive metastatic breast cancer, based on the landmark Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study.”

Introduction ¶2Find in source

paraphrase[Introduction, paragraph 4]

“Although the interim analysis of the PHILA ... showed promising results in terms of progression-free survival, the data for overall survival remained preliminary.”

PASSReviewer 2· 90% conf

The study clearly establishes its scientific foundation by citing prior work (CLEOPATRA, interim PHILA results) and providing a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 4]

“Although the interim analysis of the PHILA ... showed promising results in terms of progression-free survival, the data for overall survival remained preliminary.”

“Here, we present the prespecified final analysis of progression-free survival results, including overall survival, duration of response, and safety results after a longer follow-up period, as well as long term survival outcomes.”

Introduction ¶4Find in source

Randomization was centralized via an interactive web response system with stratification factors. Blinding of patients, investigators, and sponsor is stated. A priori power analysis is provided. Inclusion/exclusion criteria are detailed. The analysis populations (full analysis set and safety set) are defined, addressing missing data and outliers.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is well-designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Procedures]

“Randomisation was done through a centralised interactive web response system. Stratification factors included previous use of trastuzumab in neoadjuvant or adjuvant therapy (yes v no) and hormone receptor status.”

“Patients, investigators, and the sponsor were blinded to treatment allocation.”

MethodsFind in source

“Based on an assumption of a median progression-free survival of 12.5 months with trastuzumab and docetaxel, the study aimed to have 410 investigator assessed progression-free survival events to provide 80% power to detect a four month increase with the pyrotinib plus trastuzumab and docetaxel regimen (16.5 months, hazard ratio 0.76), at a one sided significance level of 0.025 for superiority.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

“Randomisation was done through a centralised interactive web response system.”

MethodsFind in source

“Patients, investigators, and the sponsor were blinded to treatment allocation.”

MethodsFind in source

“the study aimed to have 410 investigator assessed progression-free survival events to provide 80% power to detect a four month increase with the pyrotinib plus trastuzumab and docetaxel regimen (16.5 months, hazard ratio 0.76), at a one sided significance level of 0.025 for superiority.”

Statistical analysisFind in source

Sex is reported (all female) and justified by the disease context (HER2-positive breast cancer predominantly in women). Age range (18-75) is given. Demographics such as hormone receptor status and prior trastuzumab use are reported as stratification factors. Detailed baseline characteristics are said to be similar and previously reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study reports sex (all female), age range, and key demographic/clinical characteristics, though detailed baseline characteristics are referenced to prior reports.

Evidence

“590 female patients with untreated HER2 positive metastatic breast cancer.”

AbstractFind in source

paraphrase[Methods, Study design and participants]

“Participants aged 18 to 75 years with histologically confirmed HER2 positive recurrent or metastatic breast cancer...”

“Previous reports have indicated that the baseline characteristics of participants were generally similar between the two groups.”

ResultsFind in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human clinical trial, including sex, age, and health status.

Evidence

“590 female patients with untreated HER2 positive metastatic breast cancer.”

AbstractFind in source

“Participants aged 18 to 75 years with histologically confirmed HER2 positive recurrent or metastatic breast cancer, who had not received the treatment for this stage of the disease were eligible.”

MethodsFind in source

“Previous reports have indicated that the baseline characteristics of participants were generally similar between the two groups.”

ResultsFind in source

The paper states approval by the ethics committee of each study centre and that the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from all patients. The approval statement is adequate, though specific protocol numbers are not provided.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval from each study centre's ethics committee and informed consent are reported, along with compliance with the Declaration of Helsinki and GCP.

Evidence

“This study was approved by the ethics committee of each study centre (see supplementary table S9) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.”

EthicsFind in source

“All patients provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

EthicsFind in source

“All patients provided written informed consent.”

MethodsFind in source

The trial uses a drug, biologic, and chemotherapy; the investigational products are named with manufacturer (Jiangsu Hengrui Pharmaceuticals for pyrotinib) and dosing regimen. Trastuzumab and docetaxel are standard agents, and their doses are specified. Software used for statistical analysis (SAS version 9.4) is identified. No bench reagents or cell lines are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (pyrotinib, trastuzumab, docetaxel) are identified with doses and regimens, and the statistical software is identified.

Evidence

“Patients were randomly assigned in a 1:1 ratio to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg in treatment cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel on day 1 of each 21 day treatment cycle.”

MethodsFind in source

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (pyrotinib, trastuzumab, docetaxel) are adequately identified with doses and regimens.

Evidence

“Eligible patients were randomly assigned in a 1:1 ratio to receive either the irreversible pan-HER inhibitor pyrotinib (400 mg orally once daily) or placebo, both in combination with intravenous trastuzumab (8 mg/kg for the first cycle, then 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m 2 ) on day 1 of each 21 day treatment cycle.”

AbstractFind in source

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

Statistical analysisFind in source

The statistical analysis plan is detailed, naming tests (Kaplan-Meier, log-rank, Cox, Cochran-Mantel-Haenszel). Effect sizes (hazard ratios) with 95% CIs are reported for all primary and secondary endpoints. P-values are reported as nominal one-sided, which is appropriate given the prespecified alpha spending. The paper reports by estimation with CIs, so exact p-values are not required. Data presentation includes Kaplan-Meier curves and forest plots.

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are nominal one-sided as prespecified.

Evidence

paraphrase[Methods, Statistical analysis]

“The Kaplan-Meier method was used to estimate the time-to-event endpoints... and the Brookmeyer Crowley method was used to calculate the corresponding 95% confidence intervals (CIs).”

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

AbstractFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and adequately reported, with effect sizes and confidence intervals provided.

Evidence

paraphrase[Methods, Statistical analysis]

“The Kaplan-Meier method was used to estimate the time-to-event endpoints ... and hazard ratios and corresponding 95% CIs determined using the stratified Cox proportional hazards model.”

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

AbstractFind in source

“no formal hypothesis testing on overall survival was prespecified, so the results reported in this paper, for both progression-free survival and overall survival, are with nominal one sided P values.”

Statistical analysisFind in source

The data availability statement provides a specific repository (Mendeley Data) with a DOI and URL for the anonymised individual patient data. This is a concrete access route, satisfying the requirement. No bespoke code was written for analysis (SAS was used), so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

A data availability statement provides a concrete route to the anonymised individual patient data via Mendeley Data with a DOI.

Evidence

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

Data availabilityFind in source

PASSReviewer 2· 95% conf

Data availability is adequately reported with a concrete repository link.

Evidence

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

Data availabilityFind in source

Trial registration number is provided (NCT03863223). Methods are comprehensive. Limitations are explicitly discussed (absence of pertuzumab control, post-discontinuation treatments). Conclusions are proportional to the evidence. Funding sources and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI statements are provided.

Evidence

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223) .”

AbstractFind in source

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

LimitationsFind in source

paraphrase[Funding and Competing interests sections]

“Funding: This study was funded by Jiangsu Hengrui Pharmaceuticals... Competing interests: All authors have completed the ICMJE uniform disclosure form...”

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, funding/COI statements, and limitations discussed.

Evidence

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223) .”

AbstractFind in source

“Funding: This study was funded by Jiangsu Hengrui Pharmaceuticals, with partial support from the National Natural Science Foundation of China (92459304), CAMS Innovation Fund for Medical Sciences (CIFMS; 2021-I2M-1-014), and National High Level Hospital Clinical Research Funding (2025-LYZX-D-A02).”

FundingFind in source

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

LimitationsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 25 verified.

1 data/code link checked; 1 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust; an informed reader should weigh the minor internal inconsistency in the diarrhoea safety numbers and the lack of explicit CONSORT adherence, but neither undermines the main conclusions. No erratum is warranted for the minor issues, though the authors may consider a correction for the diarrhoea percentage discrepancy.

1.
HIGHcopyedit
In Results, Safety, reconcile the diarrhoea percentage in the placebo group: text says 55% (n=162) but Table 2 lists 54% (n=158). Correct the text or the table to match.
An internal inconsistency between the narrative and the table undermines data credibility and could be flagged by readers or reviewers.
2.
MEDIUMreporting
Add an explicit statement of adherence to the CONSORT reporting guideline in the Methods or a dedicated section.
Both reviewers noted the absence of an explicit reporting guideline statement, which is a minor transparency gap for a clinical trial.
3.
MEDIUMreporting
Provide more detailed demographic data (e.g., race/ethnicity, comorbidities) in the main text or supplementary tables, rather than only stating baseline characteristics were similar.
Reviewer 2 flagged demographics as 'reported_but_inadequate'; fuller reporting would strengthen the paper's transparency.
4.
MEDIUMstatistics
Clarify the handling of missing data and any sensitivity analyses in the statistical analysis section.
Reviewer 2 noted this is not explicitly described; adding it would improve methodological transparency.
5.
MEDIUMstatistics
Consider reporting exact p-values for all secondary endpoints, as some are only reported as thresholds (e.g., P<0.001).
Exact p-values would allow readers to assess the strength of evidence more precisely.
6.
MEDIUMdata code
Include a statement on whether the Mendeley Data repository is under a managed-access or open-access model, to clarify access conditions.
Reviewer 2 suggested this clarification to help readers understand how to access the data.
7.
LOWcopyedit
Fix the missing space in the Abstract/Conclusions: 'treatment ofHER2' should be 'treatment of HER2'.
Typographical error that should be corrected for professionalism.
8.
LOWcopyedit
Add 'respectively' to the Abstract Results sentence: '59 (20%) and 87 (30%) patients died' → '59 (20%) and 87 (30%) patients died, respectively'.
Improves clarity by indicating the order of the groups.
9.
LOWcopyedit
Rephrase the Discussion sentence comparing hazard ratios for clarity: 'The hazard ratio for overall survival in the pyrotinib group (0.74) was comparable to that reported for the pertuzumab arm (0.68) in the CLEOPATRA study.'
The original phrasing is slightly ambiguous; the suggested rephrase is clearer.

Full text (50,037 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Read full text (PMC)

DOI

10.1136/bmj-2025-087259

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/bad43a1e-af51-4b4c-9dba-565bea1f3cc6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/bad43a1e-af51-4b4c-9dba-565bea1f3cc6/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 1 high issue for “Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

5450a279ffdac244af0951e9ebf6ff3b494f931f1c5efa28c45bc18dd21aeb0a

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 103AuthenticityData authenticity concerns 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

None found

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

Data look implausibly cleanAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes the scientific rationale for dual HER2 blockade and the role of pyrotinib, citing the CLEOPATRA trial and prior PHILA interim results.

Evidence

Introduction ¶2Find in source

paraphrase[Introduction, paragraph 4]

“Although the interim analysis of the PHILA ... showed promising results in terms of progression-free survival, the data for overall survival remained preliminary.”

PASSReviewer 2· 90% conf

The study clearly establishes its scientific foundation by citing prior work (CLEOPATRA, interim PHILA results) and providing a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 4]

“Although the interim analysis of the PHILA ... showed promising results in terms of progression-free survival, the data for overall survival remained preliminary.”

Introduction ¶4Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is well-designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Procedures]

“Patients, investigators, and the sponsor were blinded to treatment allocation.”

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

“Randomisation was done through a centralised interactive web response system.”

MethodsFind in source

“Patients, investigators, and the sponsor were blinded to treatment allocation.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study reports sex (all female), age range, and key demographic/clinical characteristics, though detailed baseline characteristics are referenced to prior reports.

Evidence

“590 female patients with untreated HER2 positive metastatic breast cancer.”

AbstractFind in source

paraphrase[Methods, Study design and participants]

“Participants aged 18 to 75 years with histologically confirmed HER2 positive recurrent or metastatic breast cancer...”

“Previous reports have indicated that the baseline characteristics of participants were generally similar between the two groups.”

ResultsFind in source

PASSReviewer 2· 90% conf

Biological variables are adequately reported for a human clinical trial, including sex, age, and health status.

Evidence

“590 female patients with untreated HER2 positive metastatic breast cancer.”

AbstractFind in source

MethodsFind in source

“Previous reports have indicated that the baseline characteristics of participants were generally similar between the two groups.”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval from each study centre's ethics committee and informed consent are reported, along with compliance with the Declaration of Helsinki and GCP.

Evidence

EthicsFind in source

“All patients provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

EthicsFind in source

“All patients provided written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (pyrotinib, trastuzumab, docetaxel) are identified with doses and regimens, and the statistical software is identified.

Evidence

MethodsFind in source

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (pyrotinib, trastuzumab, docetaxel) are adequately identified with doses and regimens.

Evidence

AbstractFind in source

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are nominal one-sided as prespecified.

Evidence

paraphrase[Methods, Statistical analysis]

“The Kaplan-Meier method was used to estimate the time-to-event endpoints... and the Brookmeyer Crowley method was used to calculate the corresponding 95% confidence intervals (CIs).”

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

AbstractFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and adequately reported, with effect sizes and confidence intervals provided.

Evidence

paraphrase[Methods, Statistical analysis]

“The Kaplan-Meier method was used to estimate the time-to-event endpoints ... and hazard ratios and corresponding 95% CIs determined using the stratified Cox proportional hazards model.”

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

AbstractFind in source

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

A data availability statement provides a concrete route to the anonymised individual patient data via Mendeley Data with a DOI.

Evidence

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

Data availabilityFind in source

PASSReviewer 2· 95% conf

Data availability is adequately reported with a concrete repository link.

Evidence

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI statements are provided.

Evidence

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223) .”

AbstractFind in source

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

LimitationsFind in source

paraphrase[Funding and Competing interests sections]

“Funding: This study was funded by Jiangsu Hengrui Pharmaceuticals... Competing interests: All authors have completed the ICMJE uniform disclosure form...”

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, funding/COI statements, and limitations discussed.

Evidence

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223) .”

AbstractFind in source

FundingFind in source

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

LimitationsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 25 verified.

1 data/code link checked; 1 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHcopyedit
In Results, Safety, reconcile the diarrhoea percentage in the placebo group: text says 55% (n=162) but Table 2 lists 54% (n=158). Correct the text or the table to match.
An internal inconsistency between the narrative and the table undermines data credibility and could be flagged by readers or reviewers.
2.
MEDIUMreporting
Add an explicit statement of adherence to the CONSORT reporting guideline in the Methods or a dedicated section.
Both reviewers noted the absence of an explicit reporting guideline statement, which is a minor transparency gap for a clinical trial.
3.
MEDIUMreporting
Provide more detailed demographic data (e.g., race/ethnicity, comorbidities) in the main text or supplementary tables, rather than only stating baseline characteristics were similar.
Reviewer 2 flagged demographics as 'reported_but_inadequate'; fuller reporting would strengthen the paper's transparency.
4.
MEDIUMstatistics
Clarify the handling of missing data and any sensitivity analyses in the statistical analysis section.
Reviewer 2 noted this is not explicitly described; adding it would improve methodological transparency.
5.
MEDIUMstatistics
Consider reporting exact p-values for all secondary endpoints, as some are only reported as thresholds (e.g., P<0.001).
Exact p-values would allow readers to assess the strength of evidence more precisely.
6.
MEDIUMdata code
Include a statement on whether the Mendeley Data repository is under a managed-access or open-access model, to clarify access conditions.
Reviewer 2 suggested this clarification to help readers understand how to access the data.
7.
LOWcopyedit
Fix the missing space in the Abstract/Conclusions: 'treatment ofHER2' should be 'treatment of HER2'.
Typographical error that should be corrected for professionalism.
8.
LOWcopyedit
Add 'respectively' to the Abstract Results sentence: '59 (20%) and 87 (30%) patients died' → '59 (20%) and 87 (30%) patients died, respectively'.
Improves clarity by indicating the order of the groups.
9.
LOWcopyedit
Rephrase the Discussion sentence comparing hazard ratios for clarity: 'The hazard ratio for overall survival in the pyrotinib group (0.74) was comparable to that reported for the pertuzumab arm (0.68) in the CLEOPATRA study.'
The original phrasing is slightly ambiguous; the suggested rephrase is clearer.

Full text (50,037 chars)Analyzed: Aug 15, 2026